IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Adam Kois

USPTO Granted Patents = 21

 


Average Co-Inventor Count = 8.3

ph-index = 14

Forward Citations = 548(Granted Patents)


Location History:

  • Escondido, CA (US) (2003)
  • San Diego, CA (US) (1995 - 2012)

Company Filing History:

goldMedal11 out of 37 
 
Texas Biotechnology Corporation
 patents
silverMedal7 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents
bronzeMedal2 out of 3 
 
Immunopharmaceutics, Inc.
 patents
4. 1 out of 52 
 
Pharmacopeia Drug Discovery, Inc.
 patents
5. 1 out of 9 
 
Encysive Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1995-2012

Loading Chart...
Loading Chart...
Loading Chart...
21 patents (USPTO):
1. 8101588 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2012-01-24),
2. 7723340 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2010-05-25),
3. 7521446 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2009-04-21),
4. 7442699 - Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto (2008-10-28),
5. 7122544 - Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto (2006-10-17),
6. 6613804 - Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin (2003-09-02),
7. 6541498 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2003-04-01),
8. 6376523 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2002-04-23),
9. 6372739 - Compounds and methods for modulation of estrogen receptors (2002-04-16),
10. 6342610 - N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2002-01-29),
11. 6331637 - N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2001-12-18),
12. 6291456 - Compounds and methods for modulation of estrogen receptors (2001-09-18),
13. 6265428 - Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin (2001-07-24),
14. 6030991 - Benzenesulfonamides and the use thereof to modulate the activity of (2000-02-29),
15. 5977117 - Substituted phenyl compounds and derivatives thereof that modulate the (1999-11-02),

Title: Adam Kois: A Career Filled with Innovation and Success

Introduction:

Throughout his illustrious career, Adam Kois has continuously demonstrated his exceptional talent and passion for innovation. Hailing from San Diego, CA, Kois has made significant contributions to the field of biotechnology and pharmaceuticals. With an impressive portfolio of patents, Kois has been recognized for his groundbreaking work in developing novel treatments and compounds. This article delves into his latest patents, career highlights, influential collaborations, and the lasting impact of his inventions.

Latest Patents:

Adam Kois's latest patents revolve around his groundbreaking work on haloaryl substituted aminopurines, their compositions, and their applications in diverse treatment methods. These Aminopurine Compounds have demonstrated promising potential for therapeutic use, providing new avenues for combating various diseases and medical conditions. Kois's innovative approach has undoubtedly opened the door to further advancements in the medical field.

Career Highlights:

Over the course of his career, Adam Kois has accumulated an impressive patent portfolio, with a total of 21 patents to his name. Each patent showcases his ingenuity in developing innovative solutions to complex problems. Through his work, Kois has left an indelible mark on the biotechnology and pharmaceutical sectors, with his inventions poised to transform healthcare practices.

Collaborations:

Kois's remarkable achievements are not only a result of his individual brilliance but also of his collaborations with esteemed colleagues. Notably, he has worked with renowned companies such as Texas Biotechnology Corporation and Signal Pharmaceuticals, Inc. These collaborations have fostered an environment of collaboration and knowledge-sharing, enabling Kois to leverage his expertise and insights in partnership with industry leaders.

Among his coworkers, Ming Fai Chan and Vitukudi Narayanaiyengar Balaji have been indispensable contributors to Kois's research endeavors. Their collective efforts have enhanced the groundbreaking potential of Kois's inventions, further solidifying his position as an influential figure in the field.

Conclusion:

Adam Kois's remarkable career journey showcases his unwavering commitment to innovation and scientific excellence. With 21 patents and counting, his contributions have had a far-reaching impact on the biotechnology and pharmaceutical sectors. His latest patents centered around haloaryl substituted aminopurines demonstrate his ability to explore uncharted territory, revolutionizing treatment approaches for various diseases. Kois's collaborations and partnerships have also played a crucial role in bringing his inventions to fruition. Undoubtedly, Adam Kois's achievements will continue to inspire and shape the future of medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…